You have goals for every project, and your CRO should be as committed to those goals as you are. But if things take too long to get done, it might be time to switch CROs instead. Learn to spot these six signs your preclinical work needs a new CRO.
September 30, 2020
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
- What Makes Radioligand Therapy IND Strategy Fundamentally Different?
- Receptor Mediated Therapies in the Clinic: From Targeting to Impact
- A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
Bone cancers and soft tissue sarcomas represent a diverse group of rare malignancies arising from mesenchymal tissues including bone, muscle, fat, ...
How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
The FDA’s newly announced Plausible Mechanism Framework marks an important step toward aligning regulatory pathways with the realities of modern ...
What Makes Radioligand Therapy IND Strategy Fundamentally Different?
Your browser does not support the video tag.
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
